Navigation Links
TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
Date:8/27/2007

- Tezampanel Development Targeting Chronic Pain Conditions; Compound

Currently in Phase IIb Clinical Trial for Acute Migraine -

LA JOLLA, Calif., Aug. 27 /PRNewswire-FirstCall/ -- TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that it has initiated a Phase I multiple dose clinical trial to evaluate the safety, tolerability and pharmacokinetics of tezampanel given as a subcutaneous injection to healthy male and female volunteers once-daily for four consecutive days. Tezampanel, an AMPA/kainate (AK) receptor antagonist that selectively binds to certain AK receptors to potentially block the transmission of pain signals, has been administered in single doses to more than 300 patients and healthy adults. Data from this multiple dose trial will support the continued development of tezampanel for the treatment of migraine as well as allow TorreyPines to consider expanding the development of tezampanel into additional chronic pain conditions.

The double-blind, placebo-controlled, multiple-dose trial will be conducted at one center in the United States. Approximately 30 healthy male and female volunteers, between the ages of 21 and 55, will be enrolled in sequential, dose-escalating cohorts and receive once-daily subcutaneous doses of placebo or 40 mg, 70 mg or 100 mg of tezampanel for four consecutive days. These same dose strengths, given as a single dose subcutaneous injection, are currently being evaluated by TorreyPines in a Phase IIb clinical trial of tezampanel for acute migraine.

"We are pleased with our development progress for tezampanel," said Neil Kurtz, M.D., President and Chief Executive Officer of TorreyPines. "Our Phase IIb trial in migraine has completed enrollment
'/>"/>

SOURCE TorreyPines Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... N.Y. , July 24, 2014  Kinex Pharmaceuticals ... FDA for the Company,s KX2-391 Ointment for the commencement ... This is the Company,s third IND to be allowed ... KX2-391 is a synthetic, orally active and ... tubulin polymerization. KX2-391 promotes the induction of p53, G2/M ...
(Date:7/24/2014)... , July 24, 2014 Consolidated Net ... Business Highlights   , India Business grew ... by 9.33% to Rs. 4,886.70 Mn Rest of World ... Europe Formulations Business grew by 34.53% to Rs. 977.26 Mn ... , Glenmark Pharmaceuticals Limited, the research-led global ...
(Date:7/24/2014)... Boston Children,s Hospital,s Global Pediatric Summit + Awards, ... Tank" – a forum designed to give pediatric health ... product solution to a panel of acclaimed judges for ... the innovation and bring it to market. ... will be moderated by Daymond John of ...
Breaking Medicine Technology:Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 2Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 3Kinex Pharmaceuticals Announces Allowance of the Investigational New Drug (IND) application for KX2-391 Ointment by the United States Food and Drug Administration (FDA) 4Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 2Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 3Glenmark's Consolidated Revenue Increases by 20.08% to Rs. 14,869.40 Mn for Q1 FY 14 - 15 4Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 2Taking on Tomorrow to Feature "Innovation Tank" Pitch Opportunity for Aspiring Pediatric Health Care Entrepreneurs 3
... MOUNTAIN VIEW, Calif., Nov. 7, 2011 Alexza Pharmaceuticals, ... results for the fiscal quarter ended September 30, 2011 ... the quarters ended September 30, 2011 and 2010, as ... the United States (GAAP), were $13.4 million and $0.6 ...
... LIBERTY, Mo. and DANBURY, Conn., Nov. 7, 2011 ... "Planet"), a privately held specialty pharmaceutical company focused on ... that it had completed an asset sale of ALLERGY ... ACQUISITION LLC, a New Jersey limited liability company. ...
Cached Medicine Technology:Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 2Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 3Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 4Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 5Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 6Alexza Reports 2011 Third Quarter Financial Results and Provides Business Update 7
(Date:7/24/2014)... ultrasounds uncover antenatal hydronephrosis, or enlarged kidneys, the ... States. Many children with this abnormality are treated ... years of life with the hopes of preventing ... however, little evidence existed as to the benefits ... inconvenience for families. But a study published this ...
(Date:7/24/2014)... American air and missile defense radar market is estimated to ... a CAGR of 8.22% to reach $2.7 billion in 2020. ... and missile defense radar system. However, in the recent economic ... , Browse through the TOC of the North American air ... of the in-depth analysis provided. This report also provides a ...
(Date:7/24/2014)... composed of a single soul inhabiting two bodies." Poetic ... were made in heaven for each other can hurt ... observe that people talk and think about love in ... common themes that frame how we think about relationships. ... unity ("made for each other," "she,s my other half"); ...
(Date:7/24/2014)... 24, 2014 The National Resident ... launch of a new version of its smartphone app, ... PRISM, for applicants participating in NRMP’s Main Residency Match® ... track and organize program information during the interview process ... creating their rank order lists. Rank order lists ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 RxNetwork ... of prescription non-adherence at Cardinal Health RBC 2014 ... Utilizing familiar and user-friendly Mobile devices, RxNetwork is ... payers. , Already embraced by over 100 ... patients and caregivers through timely alerts and messages ...
Breaking Medicine News(10 mins):Health News:Continuous antibiotics not necessary for many children with common prenatal abnormality 2Health News:Continuous antibiotics not necessary for many children with common prenatal abnormality 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 2Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 3Health News:North America Air and Missile Defense Radar Market is Expected to Reach $2.7 Billion in 2020 - New Report by MicroMarket Monitor 4Health News:New research: When it hurts to think we were made for each other 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 2Health News:National Resident Matching Program® (NRMP®) Releases New, Enhanced Version of its Smartphone App 3Health News:RxNetwork Brings the Next Generation Customer Care Connectivity to Pharmacies, Providers, and Patients 2
... have identified two genes believed to play a role in ... to better diagnosis and treatment of this increasingly common form ... or womb cancer, is the most common malignant cancer of ... of cases being detected has increased markedly, as has mortality. ...
... While studying an HIV protein that plays an essential ... Pittsburgh School of Medicine have discovered compounds that show ... drug discovery efforts have met with little success in ... factor, called Nef, because it lacks biochemical activity that ...
... how your eyes adjust during a blackout? When we go ... must quickly adjust. Vision scientists at Washington University School of ... allows the human eye to adapt to darkness very quickly. ... bright light. The discovery could contribute to better understanding ...
... treatments instead, study finds, , TUESDAY, Oct. 13 (HealthDay News) ... cancer are not turning to mastectomy as their first choice ... as lumpectomy, a new survey has found. , The survey, ... of the American Medical Association , also found that U.S. ...
... ... Support for the Nationwide Health Information Network. , ... Chantilly, VA (PRWEB) October 13, 2009 -- Agilex Technologies, Inc. , ... and public sectors , today announced the appointment of Melissa Chapman to the ...
... fastest-growing retailer of authentic nonfat frozen yogurt, announced it ... , to celebrate the favorite food of the fall ... Spice frozen yogurt, available at all Red Mango ... 13, through December 31, 2009. , (Photo: ...
Cached Medicine News:Health News:Genes behind increasingly common form of cancer identified 2Health News:Pitt researchers find candidates for new HIV drugs 2Health News:Researchers discover mechanism that helps humans see in bright and low light 2Health News:Researchers discover mechanism that helps humans see in bright and low light 3Health News:Mastectomy Not First Choice for Most Breast Cancer Patients 2Health News:Mastectomy Not First Choice for Most Breast Cancer Patients 3Health News:Agilex Technologies Hires Former HHS CIO Melissa Chapman to Lead Health Technology Programs 2Health News:Agilex Technologies Hires Former HHS CIO Melissa Chapman to Lead Health Technology Programs 3Health News:Discover Red Mango's New Seasonal Flavor: Pumpkin Spice 2
Ideal for use with thinner casting materials such as polyester or fiberglass. Conforms to any casting material....
This lightweight cast boot features a sturdy canvas upper. The three layer EVA rocker outsole provides excellent shock absorption....
... assay for the qualitative and ... to Gliadin in human serum. ... be used as an aid ... disorders, mainly Coeliac Disease. This ...
... Myeloperoxidase IgG ELISA test system is intended ... IgG-class antibody to myeloperoxidase in human serum. ... used as an aid in the diagnosis ... elevated levels of anti-neutrophil cytoplasmic antibodies (ANCA). ...
Medicine Products: